ETHZilla Yönetim

Yönetim kriter kontrolleri 0/4

ETHZilla CEO'su McAndrew Rudisill, Sep2025 tarihinde atandı, in görev süresi bir yıldan az. şirketin hisselerinin 0.057% doğrudan sahiptir ve bu hisselerin değeri $ 58.07K dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 0.2 yıl ve 0.3 yıldır.

Anahtar bilgiler

McAndrew Rudisill

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	less than a year
CEO sahipliği	0.06%
Yönetim ortalama görev süresi	less than a year
Yönetim Kurulu ortalama görev süresi	less than a year

Son yönetim güncellemeleri

Recent updates

180 Life Sciences to raise $6.5M in direct stock offering

Jul 18

180 Life Sciences: Looking At Inflammation With Cannabis (Podcast)

Sep 08

What Type Of Shareholders Make Up 180 Life Sciences Corp.'s (NASDAQ:ATNF) Share Registry?

Feb 17

CEO

McAndrew Rudisill (46 yo)

less than a year

Görev süresi

Mr. McAndrew Rudisill, BA (Econ), is Executive Chairman of ETHZilla Corporation (formerly known as 180 Life Sciences Corp.) from August 2025 and serves as Chief Executive Officer since September 4, 2025. H...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
McAndrew Rudisill	Executive Chairman & CEO	less than a year	Veri yok	0.057% $ 58.1k
John Saunders	Senior VP & CFO	less than a year	Veri yok	Veri yok
Eric Van Lent	Chief Accounting Officer & Secretary	less than a year	Veri yok	0.0041% $ 4.2k
John Kristoff	Senior Vice President of Corporate Communications & Investor Relations	less than a year	Veri yok	Veri yok

0.2yrs

Ortalama Görev Süresi

46yo

Ortalama Yaş

Deneyimli Yönetim: ETHZ 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 0.2 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
McAndrew Rudisill	Executive Chairman & CEO	less than a year	Veri yok	0.057% $ 58.1k
Kevin Tracey	Member of Scientific Advisory Board	3.8yrs	Veri yok	Veri yok
Jason New	Director	less than a year	Veri yok	1.38% $ 1.4m
Chas Bountra	Member of Scientific Advisory Board	3.8yrs	Veri yok	Veri yok
Michael Edwards	Independent Director	no data	Veri yok	Veri yok
Crystal Heter	Independent Director	less than a year	Veri yok	0.92% $ 937.5k
Ryan Smith	Lead Independent Director	1.8yrs	US$48.33k	1.42% $ 1.5m
Andrew Suckling	Independent Director	less than a year	Veri yok	0.75% $ 764.5k
Angela Dalton	Independent Director	no data	Veri yok	Veri yok
Irene Tracey	Member of Scientific Advisory Board	3.8yrs	Veri yok	Veri yok
Sallie Lamb	Member of Scientific Advisory Board	3.8yrs	Veri yok	Veri yok

0.3yrs

Ortalama Görev Süresi

50yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ETHZ 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 0.3 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/12/24 22:10
Gün Sonu Hisse Fiyatı	2025/12/24 00:00
Kazançlar	2025/09/30
Yıllık Kazançlar	2024/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

ETHZilla Corporation 3 Bu analistlerden 0, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
James Molloy	Alliance Global Partners
Jason McCarthy	Maxim Group
Nazibur Rahman	Maxim Group

ETHZilla Yönetim

Yönetim kriter kontrolleri 0/4

Anahtar bilgiler

Son yönetim güncellemeleri

ETHZilla Corporation Appoints Angela Dalton and Michael Edwards as Independent Directors, Effective December 19, 2025

Ethzilla Corporation Promotes John T. Saunders to Chief Financial Officer

ETHZilla Corporation Appoints John Kristoff as Senior Vice President, Corporate Communications and Investor Relations

Ethzilla Announces Appointment of Jason New to Board of Directors, Effective October 8, 2025

ETHZilla Corporation Announces Chief Executive Officer Changes, Effective September 4, 2025

180 Life Sciences Corp. Announces Board Appointments

Recent updates

ETHZilla Corporation Appoints Angela Dalton and Michael Edwards as Independent Directors, Effective December 19, 2025

ETHZilla Corporation (NasdaqCM:ETHZ) acquired 20% stake in Karus, Inc. for $10 million.

Ethzilla Corporation Promotes John T. Saunders to Chief Financial Officer

ETHZilla Corporation to Report Q3, 2025 Results on Nov 14, 2025

ETHZilla Corporation Appoints John Kristoff as Senior Vice President, Corporate Communications and Investor Relations

Ethzilla Announces Appointment of Jason New to Board of Directors, Effective October 8, 2025

ETHZilla Corporation announced that it has received $350 million in funding

ETHZilla Corporation Announces Chief Executive Officer Changes, Effective September 4, 2025

ETHZilla Corporation (NasdaqCM:ETHZ) announces an Equity Buyback for $250 million worth of its shares.

180 Life Sciences Corp. has filed a Follow-on Equity Offering in the amount of $500 million.

180 Life Sciences Corp. Announces Board Appointments

180 Life Sciences Corp. announced that it expects to receive $425 million in funding from Electric Capital Partners, LLC, Polychain Capital LP, GSR, Omicron Technologies and other investors

180 Life Sciences Corp., Annual General Meeting, Jul 24, 2025

180 Life Sciences Corp. Appoints Board Committees, Effective June 17, 2025

180 Life Sciences Corp. Announces Resignation of Jay Goodman as Member of the Board of Directors, Effective June 13, 2025

180 Life Sciences Corp. Enters into A Confidential Settlement Agreement and Release with Amtrust International Underwriters DAC and Its Wholly-Owned Subsidiary, Amtrust Financial Services, Inc

180 Life Sciences Corp. Announces Executive Changes

180 Life Sciences Corp. Appoints Ryan Smith as Lead Independent Director

180 Life Sciences Corp. Appoints Steven H. Shoemaker to its Audit Committee

180 Life Sciences Corp. Announces Board Changes

180 Life Sciences Corp., Annual General Meeting, Dec 27, 2024

180 Life Sciences Corp. Appoints Jay Goodman as Independent Member of the Board of Directors and as Member of It's Audit Committee, as Well as Positions on Other Committees

180 Life Sciences Regains Compliance with Nasdaq's Minimum Stockholders' Equity Rule

180 Life Sciences Expects to Meet Nasdaq Minimum Shareholders Equity Requirement as of September 30, 2024

180 Life Sciences Corp. Announces Chief Financial Officer Changes

180 Life Sciences Corp. Announces Positive Topline Results of a Clinical Pharmacology Study Testing a New Solid Formulation of CBD with Enhanced Oral Uptake

180 Life Sciences Grants an Additional Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements

180 Life Sciences Corp. has filed a Follow-on Equity Offering in the amount of $5 million.

180 Life Sciences Corp. Provides Non-Compliance Update

New major risk - Financial position

180 Life Sciences Corp. Receives Delist Determination Letter from Nasdaq

180 Life Sciences Corp. Announces Chief Executive Officer Changes

180 Life Sciences Corp. Announces Board Resignations

180 Life Sciences Corp. Announces Resignation of Donald A. Mcgovern, as Member of the Board of Directors

Nasdaq Provides 180 Life Sciences Written Notice That It Complies with Terms of Prior Extension, Company Complies with Listing Rule 5635(d)(1)(A)

180 Life Sciences Receives a Letter from Nasdaq

High number of new directors

180 Life Sciences Corp. Receives Formal Written Scientific Response from the United Kingdom's Medicines and Healthcare Products Regulatory Agency

180 Life Sciences Receives Non-Compliance Notice From Nasdaq

180 Life Sciences Corp. Receives Non-Compliance Letter from Nasdaq

New minor risk - Share price stability

180 Life Sciences Announces an Agreement for A Clinical Pharmacology Study Testing A New Formulation of Cbd for Enhanced Oral Uptake

180 Life Sciences Corp. Provides Update on Regulatory Approval Process in the UK and US for Dupuytren's Disease Treatment

180 Life Sciences Corp., Annual General Meeting, Jul 06, 2023

180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement

180 Life Sciences Corp. has completed a Follow-on Equity Offering in the amount of $6.000001 million.

180 Life Sciences Provides Update on Progress to Seek Medicines and Healthcare Products Regulatory Agency Marketing Authorization for Anti-TNF Treatment of Early Stage Dupuytren’s Contracture

No longer forecast to breakeven

Price target decreased to US$4.00

High number of new and inexperienced directors

180 Life Sciences Receives Non-Compliance Letter from Nasdaq

180 Life Sciences Corp. Announces the First Patient Has Been Randomized in the Clinical Trial to Evaluate Anti-Tumor Necrosis Factor (TNF) for Patients with Early-Stage, Pain Predominant Frozen Shoulder

180 Life Sciences Corp. has completed a Follow-on Equity Offering in the amount of $6.500001 million.

180 Life Sciences to raise $6.5M in direct stock offering

180 Life Sciences Provides Update on Correspondence Received from U.K. and U.S. Regulatory Authorities on Pathway for Therapy That Could Prevent Progression of Early-Stage Dupuytren’s Disease

180 Life Sciences Corp. Announces Following Publication of Promising Data from A Phase 2B Dupuytren’S Trial

180 Life Sciences and University of Oxford Announce Publication of Positive Phase 2b Dupuytren’s Disease Study Results in The Lancet Rheumatology

Price target decreased to US$5.00

High number of new and inexperienced directors

180 Life Sciences Corp., Annual General Meeting, Jun 14, 2022

180 Life Sciences Corp. Provides an Update on its Anticipated Preliminary Discussion

180 Life Sciences Corp. Forms Scientific Advisory Board

Lead Independent Director recently bought US$103k worth of stock

180 Life Sciences Provides Follow-Up Information on Oxford University and the Company’s Successful Dupuytren’s Phase 2b Clinical Trial Results

180 Life Sciences: Looking At Inflammation With Cannabis (Podcast)

180 Life Sciences Corp. announced that it has received $15 million in funding

180 Life Sciences Corp. announced that it expects to receive $15 million in funding

180 Life Sciences Regains Nasdaq Compliance for Listing Rules 5605(b)(1) and 5605(c)(2)

180 Life Sciences Receives Expected Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q